Hexis Active Nicotine Engagement ETF (NICO)

The Hexis Active Nicotine Engagement ETF (NICO) is an actively managed exchange-traded fund that deliberately targets companies whose business model relies on nicotine consumption. Unlike index funds, NICO’s portfolio is constructed by a fund manager who selects individual holdings to capture what the fund sees as persistent opportunities in the nicotine-revenue space — traditional cigarette manufacturers, modern e-cigarette and vape producers, nicotine replacement-therapy makers, and other businesses positioned to benefit from consumer engagement with nicotine products.

The fund is small and specialized, appealing to investors who believe the nicotine-industry thesis — that nicotine consumption will remain persistent across demographics, that regulatory uncertainty has already been priced in, and that companies in this space offer attractive valuations and cash flows. It is among the most controversial exchange-traded products available, triggering questions about ethical investing and about what it means to knowingly hold shares in companies whose products carry significant public-health costs.

The business of nicotine: what NICO holds

The companies NICO targets span several sub-sectors united by a dependence on nicotine revenue. The largest are cigarette manufacturers — multinational companies like Philip Morris, British American Tobacco, and Japan Tobacco that derive the bulk of their sales from conventional cigarette sales, though each has begun diversifying into alternative nicotine products. Alongside them are newer players focused on e-cigarettes, heated-tobacco devices, and nicotine pouches — products designed to deliver nicotine without combustion.

Hexis, the fund’s manager, maintains discretion over the exact portfolio, but historical holdings have included traditional Big Tobacco names alongside smaller companies positioned at the frontier of nicotine innovation. Nicotine-replacement therapy manufacturers (which sell gums, patches, and lozenges) may also appear. The fund’s thesis rests on the idea that nicotine addiction is resilient and that the shift from smoking to alternative-delivery systems is not a threat to revenue but a transition — the same addicted customer base choosing a different form of the same drug.

What distinguishes NICO from a simple passive tobacco index fund is active selection. The manager makes bets on which companies within the nicotine space are best-positioned to capture consumer preferences, navigate regulation, and deliver returns. This active approach costs more than passive indexing, with expense ratios typically in the 0.70% to 1.00% range — roughly double the cost of owning a broad market index fund.

Why nicotine investments exist despite controversy

The existence of a fund dedicated to nicotine-sector stocks reveals a tension in finance. The securities markets are not gated by moral judgment; they serve investors with many different values and investment theses. Tobacco stocks have long been part of mainstream portfolios, held by pension funds and mutual funds that do not explicitly seek them out but own them as part of a broad equity portfolio. NICO makes that exposure explicit and concentrated.

From a business perspective, nicotine-sector companies have characteristics that attract certain investors. They generate substantial free cash flow — the cash they earn from operations after reinvestment — because the business model does not require heavy capital expenditure. Cigarettes, once designed, sell themselves. That steady cash flow has historically funded dividends, making tobacco stocks popular among income-focused portfolios. Demand, though declining in developed countries, has shown remarkable stickiness: despite decades of health warnings and substantial price increases, nicotine consumption remains common.

The regulatory environment adds another layer. Governments in many countries have heavily restricted smoking in public spaces, increased tax on cigarettes, and placed strict limits on marketing. From an investment angle, the question is whether these regulations have already been fully priced into current valuations and whether further deterioration is as bad as it has already been feared. For believers in that thesis, nicotine stocks trade at attractive prices because investors have grown overly pessimistic.

The modern shift: cigarettes to alternatives

A central thread running through NICO and the nicotine-investment thesis is the transition from smoked cigarettes to alternative nicotine-delivery methods. Heated-tobacco products (which heat rather than burn tobacco), e-cigarettes (which vaporize nicotine liquid), and nicotine pouches (which sit between gum and cheek) all deliver nicotine without the combustion that traditional cigarettes entail. For a company like Philip Morris, which has explicitly positioned itself as a transformation story away from cigarettes, these alternatives represent both a challenge and an opportunity.

The challenge is straightforward: if consumers switch from high-margin cigarettes to potentially lower-margin alternatives, profit may shrink. The opportunity is subtler: if those same consumers remain nicotine-addicted and willing to pay premium prices for alternatives perceived as less harmful or more modern, the companies that capture that shift can maintain profitability while repositioning away from the reputational drag of cigarettes.

NICO’s active approach bets that the fund manager can identify which companies are winning this transition and which are losing. A manager might underweight a company seen as slow to modernize or overweight one perceived as capturing market share in alternatives. These tactical bets are where active management theoretically adds value — or where it underperforms, if the manager’s views prove wrong.

Cash generation and why the fund appeals to income investors

One concrete reason NICO exists is that nicotine-sector stocks, particularly the large-cap multinational cigarette manufacturers, are among the most generous dividend payers in the equity market. A company like British American Tobacco has historically paid a dividend yield in the 8–9% range, substantially higher than the average stock or broad equity index. For an investor seeking cash income, that yield is compelling.

The high dividend reflects the nature of the business: stable, mature, generating more cash than it needs to invest in growth. Rather than reinvest those earnings in new factories or risky ventures, nicotine companies return the cash to shareholders. NICO benefits from these high dividends and passes them through to its own shareholders (minus its own expense ratio), making it attractive to investors seeking regular income.

This income focus also explains why some institutional investors, including pension funds, have held tobacco stocks despite ethical concerns — the cash yields make a real difference to a retiree’s income needs. NICO makes this income source explicit and available to any investor willing to buy into its concentrated bet.

Risks specific to nicotine stocks and NICO

The most obvious risk is regulatory. A government ban on cigarettes, a sharp increase in tobacco taxes, or a restriction on alternatives like e-cigarettes could severely damage the business models these companies rely on. While such bans are not yet law in major markets, the threat is real and non-zero. Investors in nicotine stocks are implicitly betting that regulators will not go that far, or that the companies can adapt if they do.

A second risk is litigation. Tobacco companies have faced massive lawsuits over health effects; while large settlements and smoking-restrictions have arguably already priced in known legal risks, the possibility of new litigation — perhaps over e-cigarettes or newer products with less historical data — remains.

A third is demand risk, even setting aside regulation. Smoking rates in developed countries have been falling for decades as public health messaging works. If that trend accelerates, or if younger cohorts take up nicotine at lower rates than older ones, the customer base simply shrinks. No amount of dividend-raising can offset declining revenues.

Because NICO is actively managed and concentrated (holding fewer stocks than a broad index fund), it also carries manager risk: the returns depend on whether Hexis’s active selections outperform or underperform the underlying sector. Paying for active management only makes sense if the manager can generate returns above the cost of the fee, which is not guaranteed.

How to think about NICO

NICO is a focused bet: you are not buying the stock market or a broad sector; you are buying an actively managed fund’s judgment about the nicotine-revenue space specifically. That makes sense if you believe nicotine companies are mispriced, if you believe the regulatory risk is overblown, and if you can tolerate the ethical dimension of knowingly investing in an industry whose products carry major public-health costs.

For most investors, NICO is not a core holding but a satellite position — a concentrated bet taken only with capital they can afford to lose if the thesis fails. The combination of active management, sector concentration, and the inherent risks of nicotine stocks means NICO is higher-risk and higher-cost than owning a simple broad equity index fund.